Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

PEPTONIC Medical AB: PEPTONIC medical AB: Correction of the press release published on 7 May 2025 regarding resolution from the extraordinary general meeting on 7 January 2025

Peptonic Medical
Read the release

Correction of the press release published on 7 May 2025 regarding the resolution from the extraordinary general meeting on 7 January 2025 on the reduction of share capital and reverse share split where the registered share capital was incorrect. The correct share capital and number of shares are stated below.

Shares and share capital

The board's decision thus means that the registered share capital continues to amount to SEK 42,952,081.9244 divided into 9,337,409,114 shares, each share with a quota value of SEK 0.0046.

For further information please contact:

Anna Linton, CEO of Peptonic Medical AB

E-mail: anna.linton@peptonicmedical.se

Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.